Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: A multinational self-controlled case series in Europe

Silvana Romio, Daniel Weibel, Jeanne P. Dieleman, Henning K. Olberg, Corinne S. De Vries, Cormac Sammon, Nick Andrews, Henrik Svanström, Ditte Mølgaard-Nielsen, Anders Hviid, Maryse Lapeyre-Mestre, Agnès Sommet, Christel Saussier, Anne Castot, Harald Heijbel, Lisen Arnheim-Dahlström, Par Sparen, Mees Mosseveld, Martijn Schuemie, Nicoline Van Der MaasBart C. Jacobs, Tuija Leino, Terhi Kilpi, Jann Storsaeter, Kari Johansen, Piotr Kramarz, Jan Bonhoeffer, Miriam C.J.M. Sturkenboom

Research output: Contribution to journalArticleAcademicpeer-review

34 Citations (Scopus)


Background: The risk of Guillain-Barré syndrome (GBS) following the United States' 1976 swine flu vaccination campaign in the USA led to enhanced active surveillance during the pandemic influenza (A(H1N1)pdm09) immunization campaign. This study aimed to estimate the risk of GBS following influenza A(H1N1)pdm09 vaccination. Methods: A self-controlled case series (SCCS) analysis was performed in Denmark, Finland, France, Netherlands, Norway, Sweden, and the United Kingdom. Information was collected according to a common protocol and standardised procedures. Cases classified at levels 1-4a of the Brighton Collaboration case definition were included. The risk window was 42 days starting the day after vaccination. Conditional Poisson regression and pooled random effects models estimated adjusted relative incidences (RI). Pseudo likelihood and vaccinated-only methods addressed the potential contraindication for vaccination following GBS. Results: Three hundred and three (303) GBS and Miller Fisher syndrome cases were included. Ninety-nine (99) were exposed to A(H1N1)pdm09 vaccination, which was most frequently adjuvanted (Pandemrix and Focetria). The unadjusted pooled RI for A(H1N1)pdm09 vaccination and GBS was 3.5 (95% Confidence Interval (CI): 2.2-5.5), based on all countries. This lowered to 2.0 (95% CI: 1.2-3.1) after adjustment for calendartime and to 1.9 (95% CI: 1.1-3.2) when we accounted for contraindications. In a subset (Netherlands, Norway, and United Kingdom) we further adjusted for other confounders and there the RI decreased from 1.7 (adjusted for calendar month) to 1.4 (95% CI: 0.7-2.8), which is the main finding. Conclusion: This study illustrates the potential of conducting European collaborative vaccine safety studies. The main, fully adjusted analysis, showed that the RI of GBS was not significantly elevated after influenza A(H1N1)pdm09 vaccination (RI = 1.4 (95% CI: 0.7-2.8). Based on the upper limits of the pooled estimate we can rule out with 95% certainty that the number of excess GBS cases after influenza A(H1N1)pdm09 vaccination would be more than 3 per million vaccinated.

Original languageEnglish
Article numbere82222
JournalPLoS ONE
Issue number1
Publication statusPublished - 3 Jan 2014


Dive into the research topics of 'Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: A multinational self-controlled case series in Europe'. Together they form a unique fingerprint.

Cite this